OHRP - OHR Pharmaceutical, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

OHR Pharmaceutical, Inc.

800 Third Avenue
11th Floor
New York, NY 10022
United States
212-682-8452
http://www.ohrpharmaceutical.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees3

Key Executives

NameTitlePayExercisedYear Born
Dr. Jason Scott SlakterCEO, Pres & Director220.19kN/A1958
Mr. Samuel BackenrothCFO, VP of Bus. Devel. & Sec.218.15kN/A1984
Dr. Glenn L. Stoller M.D.Chief Scientific OfficerN/AN/A1964
Dr. Marlene ModiHead of Preclinical & Regulatory AffairsN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

OHR Pharmaceutical, Inc. operates as a development stage pharmaceutical company. The company intends to merge with NeuBase Therapeutics, Inc. that focuses on advancing NeuBase's peptide-nucleic acid antisense oligonucleotide technology platform for the development of therapies to address severe and currently untreatable diseases caused by genetic mutations. OHR Pharmaceutical, Inc. is headquartered in New York, New York.

Corporate Governance

OHR Pharmaceutical, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.